[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bile-acid-elevated-serum\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bile-acid-elevated-serum":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100587254",false,"NCT06925997","Metabolic Effects of Endogenous Bile Acids After Gastric Bypass Surgery","Bile-bar","Inclusion Criteria:\n\nIntervention group\n\n* RYGB-operated ≥ 18 months prior to inclusion\n* History of diabetes prior to RYGB (HbA1c ≥48 mmol\u002Fmol or use of antidiabetic medication)\n* HbA1c \\\u003C58 mmol\u002Fmol on no antidiabetic medication or metformin alone\n* Weight change \\\u003C ±3 kg for \\>3 months at time of inclusion\n\nControl group A\n\n* No history of diabetes\n* HbA1c \\\u003C48 mmol\u002Fmol at time of inclusion\n* Fasting plasma glucose \\\u003C 7.0 mmol\u002FL at time of inclusion\n* Weight change \\\u003C ±3 kg for \\>3 months at time of inclusion Control group B\n* Type 2 diabetes (HbA1c ≥48 mmol\u002Fmol or use of antidiabetic medication at time of inclusion)\n* Weight change \\\u003C ±3 kg for \\>3 months at time of inclusion\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Haemoglobin \\\u003C 6.5 mmol\u002FL at time of inclusion\n* Fasting plasma glucose \\> 10.0 mmol\u002FL at time of inclusion\n* Prior cholecystectomy\n* Chronic or tendency to diarrhoea",true,"ALL","18 Years",{"count":19,"type":20},18,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","Non-randomized, open-label, parallel-group clinical study evaluating the effects of endogenous bile acids on changes in plasma fibroblast growth factor-19 (FGF-19) and glucose metabolism by extended depletion of circulating bile acids using colesevelam as an experimental tool in subjects operated with gastric by-pass (RYGB).",[26,27,28],"Bariatric Surgery Candidate","Bile Acid, Elevated Serum","Glucose Metabolism Disorders","RECRUITING","2025-04-11",{"date":32,"type":33},"2025-04-13","ACTUAL",{"date":35,"type":33},"2024-05-02",{"date":37,"type":20},"2028-12",{"name":39,"class":40},"Hvidovre University Hospital","OTHER",""]